Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Losartan for Prevention of Post-ERCP Pancreatitis
NCT04049734Phase 1Completed
- Sponsor
- Ain Shams University
- Start
- Jan 2015
- Primary completion
- Jan 2017
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of losartan in post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) (2 arms), sponsored by Ain Shams University. Primary endpoint: Number of participants with development of acute pancreatitis at 24 hours. Started Jan 2015; status: completed.
02
Drugs
losartan
03
Conditions
post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP)
Beyond the preview
Go deeper on NCT04049734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04049734.